Curated News
By: NewsRamp Editorial Staff
May 20, 2026
Cardio Diagnostics CEO Discusses AI-Powered Heart Disease Prevention
TLDR
- Cardio Diagnostics (CDIO) advances in Medicare reimbursement and India expansion, offering early mover advantage in precision cardiovascular medicine.
- Cardio Diagnostics uses AI-driven epigenetic and genetic testing to enable precise, personalized cardiovascular disease prevention and early detection.
- By leveraging AI and genetics, Cardio Diagnostics aims to make cardiovascular care more accessible and personalized, improving global heart health outcomes.
- CEO Dr. Meesha Dogan discussed Cardio Diagnostics' use of epigenetics and AI to revolutionize cardiovascular disease prevention on The BioMedWire Podcast.
Impact - Why it Matters
This news matters because cardiovascular disease remains the leading cause of death globally, and early detection is critical for improving outcomes. Cardio Diagnostics' use of AI and epigenetics represents a paradigm shift from reactive to proactive care, potentially enabling earlier interventions and personalized treatment plans. The company's expansion into India and progress with Medicare reimbursement signal that this technology could become widely accessible, impacting millions of patients. For investors, the completion of CPT coding and payment steps, with coverage determination underway, indicates a clear path to market adoption and revenue generation, making this a stock to watch in the precision medicine space.
Summary
Cardio Diagnostics Holdings (NASDAQ: CDIO) has taken a significant step forward in its mission to revolutionize cardiovascular disease management. In a recent episode of The BioMedWire Podcast, CEO and Co-Founder Dr. Meesha Dogan detailed the company's precision medicine approach, which leverages epigenetics, genetics, and artificial intelligence to enhance prevention and early detection of heart disease. The discussion also highlighted Cardio Diagnostics’ strategic expansion into India through partnerships with Aimil Ltd. and Dr. Lal PathLabs, broadening access to its innovative testing platform. Additionally, Dr. Dogan provided updates on the Medicare reimbursement process, noting that CPT coding and payment steps are complete, though coverage determination is still pending—a key milestone for broader adoption.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible and personalized. The company's core technology, an AI-driven Integrated Genetic-Epigenetic Engine, forms the basis of its clinical tests. By integrating genetic and epigenetic data with AI, Cardio Diagnostics aims to deliver precise insights that can transform patient care. The company's progress in India and with Medicare underscores its commitment to global reach and regulatory alignment, positioning it as a potential leader in the cardiovascular diagnostics space.
This news was disseminated by MissionIR, a specialized communications platform within the Dynamic Brand Portfolio @ IBN. MissionIR helps enhance visibility for companies in the investment community through syndicated content, press release enhancement, and social media distribution. For more information about Cardio Diagnostics, investors can visit the company’s newsroom at https://ibn.fm/CDIO.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Cardio Diagnostics CEO Discusses AI-Powered Heart Disease Prevention
